{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T09:41:14Z","timestamp":1786527674096,"version":"build-2736575974"},"reference-count":25,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background\/Objectives: Therapeutic leukapheresis is widely used to manage hyperleukocytosis in hematologic malignancies, yet the factors determining its efficacy remain incompletely defined. We aimed to identify clinical, biochemical, and procedural determinants of leukapheresis efficacy in a single-center cohort. Methods: We retrospectively analyzed 125 leukapheresis procedures performed in adult patients with hematologic malignancies between March 2012 and June 2026. At our institution, emergency leukapheresis is performed before the initiation of cytoreductive therapy, so all first procedures were treatment-na\u00efve (repeat procedures could follow cytoreductive therapy). The primary endpoint was the white blood cell (WBC) reduction rate (%). Secondary endpoints were \u226530% and \u226550% reduction. Predictors of reduction were identified using univariate tests and multivariable regression, with within-patient correlation accounted for using cluster-robust standard errors, and pre- versus post-procedure biochemical changes were assessed for paired samples. Results: The median WBC reduction was 47.9%; \u226530% and \u226550% reduction were achieved in 75% and 42% of procedures, respectively. Reduction differed significantly by diagnosis (p &lt; 0.001), being highest in ALL (57.4%) and lowest in CML (18.6%). In multivariable analysis, processed volume (\u03b2 = 0.004, p &lt; 0.001), inlet rate (\u03b2 = \u22120.43, p &lt; 0.001), acute leukemia (\u03b2 = 10.4, p = 0.040), and baseline platelet count (\u03b2 = \u22120.03, p = 0.036) were independent predictors. Leukapheresis significantly reduced LDH and uric acid levels (both p &lt; 0.001). Conclusions: Leukapheresis efficacy is determined by disease subtype and modifiable procedural parameters. Higher processed volume and acute leukemia diagnosis were associated with greater WBC reduction, while CML blast crisis responds poorly. These findings support procedure optimization to maximize cytoreduction.<\/jats:p>","DOI":"10.3390\/jcm15166235","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T09:11:36Z","timestamp":1786525896000},"page":"6235","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Disease Subtype and Procedural Determinants of Leukapheresis Efficacy: A Retrospective Single-Center Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7588-6000","authenticated-orcid":false,"given":"Sinan","family":"Mersin","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Mersin University, 33110 Mersin, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pelin","family":"Aytan","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Mersin University, 33110 Mersin, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seher","family":"Yontar","sequence":"additional","affiliation":[{"name":"Apheresis Unit, Mersin University Hospital, 33110 Mersin, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmut Bak\u0131r","family":"Koyuncu","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Mersin University, 33110 Mersin, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aycan","family":"Erkenekli","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Mersin University, 33110 Mersin, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esin O\u011fuz","family":"Kozan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ad\u0131yaman Training and Research Hospital, 02200 Ad\u0131yaman, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enver","family":"Tekin","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Mersin University, 33110 Mersin, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ey\u00fcp Naci","family":"Tiftik","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Mersin University, 33110 Mersin, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1080\/10428194.2022.2056178","article-title":"Hyperleukocytosis and leukostasis in acute and chronic leukemias","volume":"63","author":"Macaron","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1182\/blood-2014-10-551507","article-title":"How I treat hyperleukocytosis in acute myeloid leukemia","volume":"125","author":"Ehninger","year":"2015","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/hon.2292","article-title":"Leukostasis in adult acute hyperleukocytic leukemia: A clinician\u2019s digest","volume":"34","author":"Ali","year":"2016","journal-title":"Hematol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/17474086.2017.1270754","article-title":"Hyperleukocytosis and leukostasis: Management of a medical emergency","volume":"10","author":"Giammarco","year":"2016","journal-title":"Expert Rev. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Bewersdorf, J.P., and Zeidan, A.M. (2020). Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?. Cells, 9.","DOI":"10.3390\/cells9102310"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.leukres.2014.01.004","article-title":"Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: A systematic review and meta-analysis","volume":"38","author":"Oberoi","year":"2014","journal-title":"Leuk. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/jca.22043","article-title":"Guidelines on the Use of Therapeutic Apheresis in Clinical Practice\u2014Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue","volume":"38","author":"Alquist","year":"2023","journal-title":"J. Clin. Apher."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1111\/trf.15994","article-title":"Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia\u2014A systematic review and meta-analysis","volume":"60","author":"Bewersdorf","year":"2020","journal-title":"Transfusion"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/jca.22082","article-title":"Therapeutic leukocytapheresis for leukostasis in chronic lymphocytic leukemia: A case report and literature review","volume":"38","author":"Auen","year":"2023","journal-title":"J. Clin. Apher."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6426","DOI":"10.1038\/s41598-021-85918-8","article-title":"The factors influencing clinical outcomes after leukapheresis in acute leukaemia","volume":"11","author":"Lee","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41598-017-17534-4","article-title":"A hospital based retrospective study of factors influencing therapeutic leukapheresis in patients presenting with hyperleukocytic leukaemia","volume":"8","author":"Jin","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"\u010cu\u010dakovi\u0107, M., Trajkovi\u0107, L., Dini\u0107, M., Panti\u0107, N., Sablji\u0107, N., Pravdi\u0107, Z., Raji\u0107, J., Milo\u0161evi\u0107, V., Mitrovi\u0107, M., and Vidovi\u0107, A. (2025). Impact of Leukapheresis and Biological Risk Markers on Early Mortality in Patients with Hyperleukocytic Acute Myeloid Leukemia. Medicina, 62.","DOI":"10.3390\/medicina62010035"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1182\/asheducation-2014.1.457","article-title":"Leukocytapheresis for the treatment of hyperleukocytosis secondary to acute leukemia","volume":"2014","author":"Aqui","year":"2014","journal-title":"Hematol. AM Soc. Hematol. Educ. Program"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000341805","article-title":"Leukocyte Depletion by Therapeutic Leukocytapheresis in Patients with Leukemia","volume":"39","author":"Moog","year":"2012","journal-title":"Transfus. Med. Hemotherapy"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jcyt.2023.01.007","article-title":"Clinical outcomes of therapeutic leukapheresis in acute promyelocytic leukemia: A single-center retrospective cohort study","volume":"25","author":"Lee","year":"2023","journal-title":"Cytotherapy"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.transci.2017.11.002","article-title":"Leukapheresis do not improve early death rates in acute myeloid leukemia patients with hyperleukocytosis","volume":"56","author":"Malkan","year":"2017","journal-title":"Transfus. Apher. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1046\/j.1365-2141.1997.1943011.x","article-title":"Therapeutic leukapheresis in hyperleucocytic leukaemias: Lack of correlation between degree of cytoreduction and early mortality rate","volume":"98","author":"Porcu","year":"1997","journal-title":"Br. J. Haematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.transci.2011.01.005","article-title":"Large volume leukapheresis: Efficacy and safety of processing patient\u2019s total blood volume six times","volume":"44","author":"Bojanic","year":"2011","journal-title":"Transfus. Apher. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/trf.14329","article-title":"The effect of therapeutic leukapheresis on early complications and outcomes in patients with acute leukemia and hyperleukocytosis: A propensity score-matched study","volume":"58","author":"Choi","year":"2017","journal-title":"Transfusion"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/j.1537-2995.2007.01406.x","article-title":"Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis","volume":"47","author":"Bug","year":"2007","journal-title":"Transfusion"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3109\/10428190109097677","article-title":"Leukapheresis Reduces Early Mortality in Patients with Acute Myeloid Leukemia with High White Cell Counts But Does Not Improve Long Term Survival","volume":"42","author":"Giles","year":"2001","journal-title":"Leuk. Lymphoma"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1038\/s41375-020-0783-3","article-title":"Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: A large, retrospective, multicenter, international study","volume":"34","author":"Stahl","year":"2020","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1007\/s00277-015-2472-2","article-title":"Hyperleukocytosis in acute myeloid leukemia patients is associated with high 30-day mortality which is not improved with leukapheresis","volume":"94","author":"Wong","year":"2015","journal-title":"Ann. Hematol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/16\/6235\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T09:23:29Z","timestamp":1786526609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/16\/6235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":25,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["jcm15166235"],"URL":"https:\/\/doi.org\/10.3390\/jcm15166235","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]}}}